Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.